Recent News
May 11, 2022
Satsuma Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

South San Francisco, CA, May 11, 2022 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel...

May 10, 2022
Satsuma Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights

South San Francisco, CA, May 10, 2022 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel...

Stock Info
NASDAQSTSA